US PTAB IP Litigation
8,574 annotated decisions
Page 156 of 358 · 8,574 total
patent
LG Display Co., Ltd. et al. v.--
· PGR2026-00028
LG Display has filed a Post‑Grant Review petition challenging U.S. Patent 12,293,691 covering an OLED display device. The petition asserts indefiniteness, lack of written description, lack of enablement, and obviousness over multiple prior‑art references. The Board has not yet ruled on the petition.
patent
Arm Ltd. v.ICPillar LLC
· IPR2024-00476
ICPillar LLC requests Director review of the PTAB’s decision to institute an IPR against Arm Ltd.’s semiconductor‑device patent. The patent owner argues the panel misapplied Fintiv guidance and should deny institution due to untimely stipulations and parallel district‑court litigation.
patent
Monolithic Power Systems, Inc. v.Greenthread, LLC
· IPR2024-00470
Greenthread seeks a PTAB Director Review to overturn the Board’s claim construction that narrows the carrier‑movement limitation of its semiconductor patent. The owner argues the construction conflicts with the specification, prosecution history, and district‑court rulings, and that the cited references do not teach the required functionality.
patent
Dr. Reddy's Laboratories S.A. et al. v.Eye Therapies, LLC et al.
· IPR2024-00467
Dr. Reddy’s labs and Eye Therapies have jointly filed a motion to keep their settlement agreement confidential and separate from the IPR docket. The request cites statutory authority and seeks limited disclosure.
patent
Paragon 28, Inc. v.Treace Medical Concepts, Inc.
· PGR2026-00031
Paragon 28 seeks to invalidate Treace’s 12,349,941 bunion‑correction patent, alleging lack of written description, enablement, and obviousness over prior surgical methods and devices. The petition requests cancellation of all 27 claims.
patent
Texas Instruments Incorporated v.Greenthread, LLC
· IPR2024-00673
The PTAB granted Director Review of the Final Written Decisions in Texas Instruments’ IPRs against Greenthread, vacated those decisions, and remanded the cases for further proceedings, ordering new discovery on the privity issue.
patent terminated or settled
Ilooda Co., Ltd. et al. v.Serendia, LLC
· IPR2024-00463
The Board granted a joint motion to terminate the IPR as to Jeisys Medical Inc. following a settlement with Serendia, while allowing EndyMed petitioners to continue the review.
patent
lululemon usa inc. et al. v.Nike, Inc.
· IPR2024-00460
Nike has filed a Director Review request challenging the PTAB’s finding that all 21 claims of its ’749 footwear‑knitting patent are unpatentable. The Owner contends the Board erred by disregarding the petitioner’s expert testimony and by incorrectly finding that the Nishida reference anticipates the claims.
patent
Albaugh, LLC v.BASF SE et al.
· PGR2026-00026
Albaugh, LLC petitions the PTAB to invalidate claims 1‑6 of BASF’s 2025 glufosinate formulation patent, asserting anticipation by the Long patent and obviousness over Long alone or combined with synthesis references.
patent
Monolithic Power Systems, Inc. v.Greenthread, LLC
· IPR2024-00468
Greenthread, LLC has filed a Request for Director Review challenging the PTAB’s claim construction in a power‑semiconductor patent owned by Monolithic Power Systems. The owner contends the Board’s construction mischaracterizes the claims and that the cited references do not teach the required carrier‑movement limitation.
patent
Samsung Electronics Co., Ltd. et al. v.--
· PGR2026-00043
Samsung has filed a PGR petition seeking cancellation of Whirlpool’s 12,543,922 dishwasher rack patent on obviousness and indefiniteness grounds, relying on multiple prior‑art references.
patent
Ilooda Co., Ltd. et al. v.Serendia, LLC
· IPR2024-00463
Serendia seeks Director Review to vacate the Board’s institution of an IPR against its dermatological device patent after the ITC upheld the patent’s validity. The request cites the recent recission of the Fintiv memo and extraordinary circumstances that favor a discretionary denial under § 314(a).
patent terminated or settled
Ilooda Co., Ltd. et al. v.Serendia, LLC
· IPR2024-00463
Jeisys Medical Inc. and Serendia, LLC have settled their dispute over U.S. Patent 10,869,812. The parties filed a joint motion to terminate the inter partes review, citing the settlement and lack of substantive briefing.
patent
MICROSOFT CORPORATION et al. v.LiTL LLC
· IPR2024-00458
Microsoft filed a Director Review Request challenging the PTAB’s denial of institution in IPR2024-00458 against LiTL’s patent. The petitioner alleges arbitrary evaluation of references and inconsistency with a prior panel decision.
patent terminated or settled
SAP America, Inc. v.ISIX IP LLC
· IPR2024-00615
SAP America and ISIX IP reached a settlement, leading to a joint motion that terminated the inter partes review of patent 6,308,178. The Board granted the termination and ordered the settlement agreement to remain confidential.
patent
Paragon 28, Inc. v.TREACE MEDICAL CONCEPTS, INC.
· PGR2026-00020
Paragon 28 seeks to invalidate Treace Medical Concepts' 12,268,428 bunion‑correction patent, alleging that all 30 claims are anticipated or obvious over well‑known surgical textbooks and prior‑art patents. The petition lists ten grounds covering §§102 and 103 and requests the Board to institute review and cancel the claims.
patent
MICROSOFT CORPORATION et al. v.LiTL LLC
· IPR2024-00457
Microsoft filed a Director Review Request challenging the PTAB’s denial of institution in IPR2024-00457 against LiTL’s patent 9,880,715. The petitioner alleges arbitrary reasoning and inconsistency with a prior panel decision.
patent
Micron Technology, Inc. et al. v.Netlist, Inc.
· IPR2024-00370
Micron seeks to invalidate five claims of Netlist’s memory‑module patent, arguing anticipation and obviousness over Osanai, Tokuhiro, and Takefman references, and requests the PTAB to institute the IPR.
patent
MICROSOFT CORPORATION et al. v.LiTL LLC
· IPR2024-00457
Microsoft and other petitioners seek Director review of a PTAB denial to institute an IPR on U.S. Patent 9,880,715, alleging the Board misapplied obviousness standards and treated the case inconsistently with a related granted IPR.
patent
Ascendis Pharma A/S et al. v.BioMarin Pharmaceutical Inc.
· PGR2026-00013
Ascendis Pharma has filed a PGR petition seeking cancellation of BioMarin’s U.S. Patent 12,331,106 covering CNP‑variant treatments for achondroplasia. The petition alleges obviousness, anticipation, lack of enablement, and an improper dependent claim. The Board must decide whether to institute the review.
patent
Terumo BTC, Inc v.Haemonetics Corporation
· PGR2026-00009
Terumo BCT has filed a post‑grant review petition challenging all 30 claims of Haemonetics’ plasma‑collection patent, arguing anticipation, obviousness, lack of written description, and patent‑ineligible subject matter. The petition relies on multiple prior‑art references covering blood‑fractionation and calculation methods.
patent
Terumo BTC, Inc v.Haemonetics Corporation
· PGR2026-00009
Terumo BCT has filed a corrected PGR petition challenging Haemonetics' plasma‑collection patent (US 12,324,873). The petition alleges anticipation, obviousness, lack of written description, and patent‑ineligible subject matter. The Board must decide whether to institute the review.
patent denied
Comcast Corporation et al. v.Entropic Communications LLC
· IPR2024-00446
The USPTO denied Comcast’s request for Director Review of the IPR decision on Entropic’s patent 8,223,775, leaving the original outcome intact.
patent instituted
Texas Instruments Incorporated v.Greenthread, LLC
· IPR2024-00673
Texas Instruments petitioned to challenge Greenthread’s semiconductor patent and sought joinder with a related IPR. The PTAB found a reasonable likelihood of unpatentability and granted both institution and joinder, merging the proceeding into IPR2023-01242.
